MX2023011102A - Anticuerpos anti-klrg1. - Google Patents

Anticuerpos anti-klrg1.

Info

Publication number
MX2023011102A
MX2023011102A MX2023011102A MX2023011102A MX2023011102A MX 2023011102 A MX2023011102 A MX 2023011102A MX 2023011102 A MX2023011102 A MX 2023011102A MX 2023011102 A MX2023011102 A MX 2023011102A MX 2023011102 A MX2023011102 A MX 2023011102A
Authority
MX
Mexico
Prior art keywords
antibodies
klrg1
antigen
binding fragments
klrg1 antibodies
Prior art date
Application number
MX2023011102A
Other languages
English (en)
Spanish (es)
Inventor
Stefano V Gulla
Kenneth Evan Thompson
Original Assignee
Abcuro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abcuro Inc filed Critical Abcuro Inc
Publication of MX2023011102A publication Critical patent/MX2023011102A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023011102A 2021-03-26 2022-03-25 Anticuerpos anti-klrg1. MX2023011102A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163166663P 2021-03-26 2021-03-26
US202163294436P 2021-12-29 2021-12-29
PCT/US2022/021945 WO2022204514A1 (en) 2021-03-26 2022-03-25 Anti-klrg1 antibodies

Publications (1)

Publication Number Publication Date
MX2023011102A true MX2023011102A (es) 2023-11-28

Family

ID=81385062

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011102A MX2023011102A (es) 2021-03-26 2022-03-25 Anticuerpos anti-klrg1.

Country Status (10)

Country Link
US (1) US20240174754A1 (https=)
EP (1) EP4314066A1 (https=)
JP (1) JP2024515165A (https=)
KR (1) KR20230162798A (https=)
AU (1) AU2022246164A1 (https=)
BR (1) BR112023019512A2 (https=)
CA (1) CA3212311A1 (https=)
IL (1) IL307241A (https=)
MX (1) MX2023011102A (https=)
WO (1) WO2022204514A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021004553A2 (pt) 2018-09-17 2021-06-08 Abcuro, Inc. anticorpos anti-klrg1

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
JP2019518791A (ja) * 2016-06-03 2019-07-04 ザ・ブリガム・アンド・ウィメンズ・ホスピタルＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ Ｋｌｒｇ１シグナリングセラピー
WO2019169229A1 (en) * 2018-03-01 2019-09-06 Nextcure, Inc. Klrg1 binding compositions and methods of use thereof
BR112021004553A2 (pt) * 2018-09-17 2021-06-08 Abcuro, Inc. anticorpos anti-klrg1
AU2020272939A1 (en) * 2019-04-09 2021-11-11 Abcuro, Inc. Killer cell lectin-like receptor subfamily G member 1 (KLRG1) depleting antibodies

Also Published As

Publication number Publication date
WO2022204514A1 (en) 2022-09-29
AU2022246164A9 (en) 2024-02-22
CA3212311A1 (en) 2022-09-29
BR112023019512A2 (pt) 2023-10-31
AU2022246164A1 (en) 2023-09-28
JP2024515165A (ja) 2024-04-05
KR20230162798A (ko) 2023-11-28
IL307241A (en) 2023-11-01
US20240174754A1 (en) 2024-05-30
EP4314066A1 (en) 2024-02-07

Similar Documents

Publication Publication Date Title
ZA202308021B (en) Anti-ctla4 antibodies and methods of making and using the same
MX2025008993A (es) Anticuerpos anti-klrg1
PH12021500031A1 (en) Anti-il2 receptor gamma antigen-binding proteins
NZ777032A (en) Anti-nkg2a antibodies and uses thereof
ZA202202363B (en) Antibodies against ilt2 and use thereof
MY208785A (en) Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
WO2018183888A3 (en) Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
EA202090372A1 (ru) Универсальные соединения авт и их применение
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
WO2020076969A3 (en) Anti-lap antibody variants and uses thereof
RU2757308C2 (ru) Введение сконструированных т-клеток для лечения рака центральной нервной системы
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
EA202092518A1 (ru) Композиции и способы лечения рака
SA523440622B1 (ar) أجسام مضادة
ZA202302392B (en) Antibodies against ilt2 and use thereof
MY200162A (en) Anti-gitr antibodies and uses thereof
MX2020008122A (es) Anticuerpos anti-pd-1.
EA202092302A1 (ru) Антитела к trem-1 и их применения
EP4530296A3 (en) Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
MX2020009902A (es) Anticuerpos con especificidad dual para pd-l1 y pd-l2 humanos y metodos de uso de los mismos.
MX2023011102A (es) Anticuerpos anti-klrg1.
EA202192964A1 (ru) Комбинированная терапия
ZA202205813B (en) Trpv1 epitopes and antibodies
MX2022004058A (es) Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo.
EA202092151A1 (ru) Антитела